AstraZeneca PLC (NASDAQ: AZN) saw its shares surge nearly 3% on Monday, significantly outpacing the broader market, fueled by a potent dual catalyst: promising late-stage trial data for a key pipeline drug and a quarterly earnings report that smashed analyst estimates.
The primary driver was the positive news from the phase 3 clinical trial for baxdrostat, an investigational treatment for treatment-resistant hypertension. AstraZeneca announced that the trial successfully met its primary endpoint, demonstrating a statistically significant and clinically meaningful reduction in the 24-hour average systolic blood pressure compared to a placebo. The drug also hit key secondary endpoints.
This breakthrough brings hope for AstraZeneca’s potential entry into a massive addressable market. The company estimates that hypertension affects over 1 billion people globally, with approximately 50% of patients failing to achieve controlled blood pressure with existing treatments. AstraZeneca placed a major bet on baxdrostat, acquiring it through the $1.8 billion takeover of CinCor Pharma in early 2023.
The bullish sentiment was further bolstered by the company’s impressive financial performance. AstraZeneca reported Q1 revenue of $15.2 billion, a 12% year-over-year increase, driven by growth across all therapy areas—most notably in Oncology (up 16%) and Respiratory & Immunology (up 13%).
Profitability was even more striking. The company posted a non-GAAP operating profit of nearly $5 billion, a 16% jump, resulting in earnings per share (EPS) of $2.38. This figure dramatically exceeded consensus analyst estimates, which had projected EPS of just $1.22. Revenue also came in above the average forecast of under $14.8 billion.
Looking ahead, AstraZeneca reaffirmed its full-year 2025 guidance, anticipating high single-digit percentage revenue growth and low double-digit percentage growth in adjusted EPS at constant exchange rates.
The combination of a potential blockbuster drug moving closer to market and robust financial health positions AstraZeneca strongly for future growth, exciting investors and driving the day’s significant stock outperformance.
